Successful outpatient parenteral antimicrobial therapy with rezafungin for chronic pulmonary aspergillosis: a case report and health economic assessment
Abstract
Background: Chronic pulmonary aspergillosis (CPA) is a serious lung disorder caused by Aspergillus fungal infection with high morbidity and mortality. Treatment options include antifungal azoles, polyenes and echinocandins. Rezafungin is a novel, once-weekly echinocandin that may benefit CPA management in outpatient parenteral antimicrobial therapy (OPAT) services.
Objectives: To report a case where rezafungin was potentially effective in managing CPA for a patient with limited treatment options, and to estimate the health economic impact of rezafungin versus once-daily echinocandin in an OPAT setting.
Patients and methods: We discuss a patient with CPA, diagnosed in 2020, with frequent episodes of haemoptysis, dyspnoea, productive cough and lethargy with progressive bilateral pulmonary cavitatory lesions and nodules treated with rezafungin over 12 weeks via OPAT. Costs to deliver once-weekly rezafungin compared with once-daily caspofungin in the OPAT clinic were compared.
Results: Symptoms improved significantly after 12 weeks of rezafungin, with no further emergency visits, versus eight in the year prior due to CPA symptoms. Aspergillus serology (IgG) improved and computerized tomography imaging showed slight improvement in the degree of consolidation surrounding the cavities. Daily OPAT costs increased by £13.71 for rezafungin compared with caspofungin. This was offset by greater patient convenience and improved OPAT clinic capacity.
Conclusions: Rezafungin may be a…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.